The analysis has included an evaluation of key strategic therapeutic areas, relevant application areas, associated infection rates, regulatory approval timelines, partner timelines and potential for commercial scale-up, describes the company.

“After a year of our license-focused strategy, we are refining our selected therapeutic areas and relevant application areas to focus where our technology has the greatest realizable potential. This is reflected in our updated strategic partnership and financial targets. With our strengthened capabilities and continued investments in R&D, regulatory expertise and new business development, we are well positioned to seize the opportunities for our infection prevention technology. We have set targets for 2030, but the potential for our technology in the longer term is even more significant. The operational leverage and economies of scale inherent in our business model are expected to become even more significant after 2030, through the partnerships announced in the coming years,” states Christine Lind, CEO of Bactiguard.

Related article

#WAAW: Mini-Interview Bactiguard

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally.


Five strategic therapy areas

As a result of the review, Bactiguard will focus on five strategic therapy areas: orthopedics, vascular access, cardiology, neurology and urology.

The updated strategic and financial goals include partnership development (have at least ten application areas in either exclusivity or licensing partnerships by the end of 2030), revenue (deliver revenues of at least SEK 600 million by the end of 2030), and EBITDA (deliver an EBITDA of at least SEK 200 million by the end of 2030).

Bactiguard will continue to focus on EBITDA profitability and cost discipline, it states. The financial targets cover both the licensing business and the wound care product portfolio. The wound care portfolio is expected to remain profitable and generate double-digit growth, the company states further.